Neumora Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Neumora Therapeutics Inc Company

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Neumora Therapeutics Inc Info



Ticker SymbolNMRA

Company nameNeumora Therapeutics Inc

IPO dateSep 15, 2023

CEOMr. Paul L. Berns

Number of employees110

Security typeOrdinary Share

Fiscal year-endSep 15

Address490 Arsenal Way

CityWATERTOWN

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02472

Phone18577600900

Websitehttps://neumoratx.com/

Ticker SymbolNMRA

IPO dateSep 15, 2023

CEOMr. Paul L. Berns

Company Executives of Neumora Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+3.27%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+46.75%

Ms. Kristina M. Burow

Independent Director

47.72K

+72.78%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-8.09%

Dr. Joshua Pinto, Ph.D.

President

--

Mr. Matthew K. (Matt) Fust

Independent Director

--

Mr. Jason G. Duncan

Chief Legal and Administrative Officer

--

Dr. Maykin Ho, Ph.D.

Independent Director

--

-100.00%

Mr. David Piacquad

Independent Director

--

Mr. Alaa A. Halawa

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+3.27%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+46.75%

Ms. Kristina M. Burow

Independent Director

47.72K

+72.78%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-8.09%

Dr. Joshua Pinto, Ph.D.

President

--

Mr. Matthew K. (Matt) Fust

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Thu, Oct 2

Shareholders

Shareholder Types

Shareholders

Proportion

Amgen Inc

21.84%

ARCH Venture Partners

20.90%

Berns (Paul L)

4.74%

SB Global Advisers Ltd

4.04%

Invus Public Equities Advisors, LLC

2.69%

Other

45.79%

Shareholders

Proportion

Amgen Inc

21.84%

ARCH Venture Partners

20.90%

Berns (Paul L)

4.74%

SB Global Advisers Ltd

4.04%

Invus Public Equities Advisors, LLC

2.69%

Other

45.79%

Shareholder Types

Shareholders

Proportion

Venture Capital

22.04%

Corporation

21.84%

Investment Advisor

21.62%

Individual Investor

5.65%

Hedge Fund

5.33%

Investment Advisor/Hedge Fund

3.10%

Endowment Fund

2.04%

Research Firm

0.70%

Family Office

0.05%

Other

17.61%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

293

86.79M

53.64%

-40.47M

2025Q2

288

142.02M

87.70%

-25.57M

2025Q1

283

144.00M

90.43%

+12.16M

2024Q4

249

161.18M

99.54%

+45.20M

2024Q3

201

148.65M

93.66%

+40.67M

2024Q2

179

142.61M

90.03%

+47.65M

2024Q1

154

133.89M

85.01%

+50.39M

2023Q4

108

122.49M

78.90%

+50.97M

2023Q3

54

110.63M

71.42%

+110.63M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Amgen Inc

35.37M

21.84%

--

Apr 10, 2025

ARCH Venture Partners

31.93M

19.72%

--

Nov 12, 2024

Berns (Paul L)

7.68M

4.74%

+242.77K

+3.27%

Apr 10, 2025

SB Global Advisers Ltd

6.54M

4.04%

--

Jun 30, 2025

Invus Public Equities Advisors, LLC

4.36M

2.69%

--

Jun 30, 2025

The Vanguard Group, Inc.

4.76M

2.94%

-562.13K

-10.56%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.50M

2.16%

+6.35K

+0.18%

Jun 30, 2025

Wellcome Trust

3.31M

2.04%

--

Jun 30, 2025

ICONIQ Capital, LLC

2.56M

1.58%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.55M

1.58%

-3.09M

-54.78%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

iShares Biotechnology ETF

0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0%

Schwab U.S. Small-Cap ETF

0%

iShares US Small-Cap Equity Factor ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

Fidelity MSCI Health Care Index ETF

0%

Schwab U.S. Broad Market ETF

0%

ProShares Ultra Nasdaq Biotechnology

Proportion0.03%

Invesco Nasdaq Biotechnology ETF

Proportion0.03%

Invesco RAFI US 1500 Small-Mid ETF

Proportion0.01%

iShares Biotechnology ETF

Proportion0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion0%

Schwab U.S. Small-Cap ETF

Proportion0%

iShares US Small-Cap Equity Factor ETF

Proportion0%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0%

Fidelity MSCI Health Care Index ETF

Proportion0%

Schwab U.S. Broad Market ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data